Yazan Migdady
Overview
Explore the profile of Yazan Migdady including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niehus H, Sabile J, Maziarz R, Meyers G, Cook R, Gandhi A, et al.
Acta Haematol
. 2024 Jun;
:1-10.
PMID: 38934131
Introduction: CMML is a rare neoplasm with overlapping myelodysplastic and myeloproliferative features whose only potential cure is allogeneic hematopoietic cell transplantation (allo-HCT). Methods: This retrospective study examined 27 CMML patients...
2.
Sabile J, Kaempf A, Tomic K, Manu G, Swords R, Migdady Y
Leuk Lymphoma
. 2023 Jul;
64(10):1689-1694.
PMID: 37440338
A molecular scoring system (IPSS-M) was recently proposed for myelodysplastic syndrome (MDS). We conducted a retrospective study of adults with MDS referred 2019-2021. The primary outcomes were leukemia-free survival (LFS)...
3.
Sabile J, Pavletic S, Migdady Y
Cancer J
. 2023 May;
29(3):179-187.
PMID: 37195774
Myelodysplastic syndromes (MDSs) are characterized by a clonal proliferation of hematopoietic stem cells with potential life-threatening cytopenia(s) and transformation to acute myeloid leukemia. Individualized risk stratification is evolving with new...
4.
Migdady Y, Pang Y, Kalsi S, Childs R, Arai S
Blood Adv
. 2021 Dec;
6(8):2707-2721.
PMID: 34972204
Anemia after allogeneic hematopoietic stem cell transplantation (HSCT) can be immune or non-immune mediated. Auto- or alloimmunity resulting from blood group incompatibility remains an important cause in post-HSCT immune-mediated anemia....
5.
Strich J, Tian X, Samour M, King C, Shlobin O, Reger R, et al.
Clin Infect Dis
. 2021 Sep;
75(1):e491-e498.
PMID: 34467402
Background: Coronavirus disease 2019 (COVID-19) requiring hospitalization is characterized by robust antibody production, dysregulated immune response, and immunothrombosis. Fostamatinib is a novel spleen tyrosine kinase inhibitor that we hypothesize will...
6.
Migdady Y, Ediriwickrema A, Jackson R, Kadi W, Gupta R, Socola F, et al.
Blood Adv
. 2020 Mar;
4(5):815-818.
PMID: 32119735
No abstract available.
7.
Bosboom J, Klanderman R, Migdady Y, Bolhuis B, Veelo D, Geerts B, et al.
Transfus Med Rev
. 2019 Mar;
33(2):69-77.
PMID: 30853167
For 30 years, transfusion-associated circulatory overload (TACO) has been recognized as a serious transfusion complication. Currently, TACO is the leading cause of transfusion-related morbidity and mortality worldwide which occurs in...
8.
Klanderman R, Bosboom J, Migdady Y, Veelo D, Geerts B, Murphy M, et al.
Transfusion
. 2018 Nov;
59(2):795-805.
PMID: 30488959
Background: Transfusion-associated circulatory overload (TACO) is the leading cause of transfusion-related major morbidity and mortality. Diagnosing TACO is difficult because there are no pathognomonic signs and symptoms. TACO biomarkers may...
9.
Migdady Y, Barnard J, Al Ali N, Steensma D, DeZern A, Roboz G, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Jun;
18(8):528-532.
PMID: 29937400
Background: Recurrent somatic mutations in SF3B1 have been identified in patients with myelodysplastic syndromes (MDS) and are associated with ring sideroblasts (RS) and relatively favorable clinical outcomes. The 2016 World...
10.
Salhab M, Migdady Y, Donahue M, Xiong Y, Dresser K, Walsh W, et al.
J Immunother Cancer
. 2018 May;
6(1):42.
PMID: 29843803
Background: Extrapulmonary small cell carcinomas (ESCC) are rare but aggressive tumors. Relapses are common despite treatment with chemotherapy and/or radiotherapy. Prospective data for treatment of ESCC are lacking; treatment of...